ClinicalTrials.gg
CompletedNCT02537028Updated Oct 9, 2017

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

A Phase 1 interventional study of MSC2364447C and MSC2364447C in Lupus Erythematosus, Systemic, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-10-09.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.

Enrollment
11th of 12
24 · median 280
Started
2015
the only one that year
Phase 1
2 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 11th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 1, and was the 5th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • MSC2364447C
  • Phase 1
  • BTK inhibitor
  • Systemic Lupus Erythematosus
  • M2951
  • Lupus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of 18 to 65 years of age
  • Diagnosis of systemic lupus erythematosus (SLE) (at least 4 of the 11 American College of Rheumatology [ACR] classification criteria for SLE) of at least 6 months duration at the Screening visit
  • Positive test results for anti-nuclear antibody (ANA) (human epithelial cell-2 ANA greater than or equal to [>=] 1:80) and/or anti-dsDNA antibody (>= 30 international units per milliliter [IU/mL]) at the Screening visit
  • At least 1 SLE disease manifestation (assessed by Systemic Lupus Erythematosus Disease Activity Index-2000 [SLEDAI-2K]) other than positive antidsDNA and no central nervous system (CNS) SLE (psychosis, organic brain syndrome, cranial nerve disorder, lupus headache, or new-onset cerebrovascular accident)
  • History of vaccinations as follows or vaccination against these pathogens during Screening:

    1. Vaccination against Streptococcus pneumoniae with pneumococcal polysaccharide vaccine 23 or pneumococcal 13-valent conjugate vaccine as per local guidelines, and
    2. Vaccination against influenza virus (as per local seasonal recommendations). Subjects receiving 1 or more of these vaccinations during screening must have at least 2 weeks between the vaccination(s) and the date of randomization at Day 1.
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Active CNS SLE
  • Initiation or change in dose of anti-malarial treatment after the screening visit
  • Within 2 weeks prior to Screening or during Screening: use of oral greater than (>) 40 mg daily prednisone equivalent, use of any injectable corticosteroids, or change in dose of corticosteroids
  • Within 2 weeks prior to Screening, initiation or change in dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, or nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Within 2 months prior to Screening or during Screening: initiation of or change in dose of methotrexate, mycophenolate (mofetil or sodium), or azathioprine
  • Within 2 months prior to Screening or during Screening, use of cyclosporine, tacrolimus, leflunomide, abatacept, anti-tumor necrosis factor alpha agents, intravenous immunoglobulin, plasmapheresis, or other disease-modifying, , or immunomodulatory therapies not otherwise specified in protocol
  • Within 6 months prior to Screening or during Screening: use of cyclophosphamide or chlorambucil
  • Within 12 months prior to screening or during screening: use of rituximab, belimumab, or any other B cell-depleting or modulating therapies
  • Within 1 month prior to Screening or during Screening, vaccination with live or .
  • Active clinically significant viral, bacterial or fungal infection, or any serious episode of infection requiring hospitalization within the last 6 months - Estimated by the Modification of Diet in Renal Disease equation of less than (\<) 60 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2), or recent decline in kidney function, or proteinuria >= 3 gram per day (g/day) (spot urine protein/creatinine ratio >= 3 mg/mg)
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    MSC2364447C 25 mg

    Drug: MSC2364447C

  • Experimental
    MSC2364447C 75 mg

    Drug: MSC2364447C

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.

    Also known as: M2951, Evobrutinib

  • Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.

    Also known as: M2951, Evobrutinib

  • DrugPlacebo

    Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Number of subjects with treatment emergent adverse events (TEAEs)

    TEAEs will be defined as the adverse events (AEs) that occur between first dose of study drug administration up to 4 weeks after the last dose of study drug administration that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the first dose of study drug administration up to 4 weeks after the last dose of study drug administration

  2. Number of subjects with TEAEs according to severity

    The severity of TEAEs will be graded using National cancer institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v 4.03) definitions of Grade 1 through Grade 5 following his/her best medical judgment. The severity of the AEs will be classified as follows: Grade 1 or mild, Grade 2 or moderate, Grade 3 or severe, Grade 4 or life-threatening and Grade 5 or death.

    Time frame: From the first dose of study drug administration up to 4 weeks after the last dose of study drug administration

  3. Number of subjects with clinically significant laboratory abnormalities

    Clinical laboratory parameters being monitored for safety will be summarized using descriptive statistics, by postdose shifts relative to Baseline for relevant parameters using relevant cut-offs. Clinical significance will be determined by investigator.

    Time frame: screening up to Day 56

  4. Number of subjects with clinically significant abnormal vital signs: blood pressure, pulse rate, respiratory rate

    Observed values and changes from Baseline in vital signs will be summarized for each treatment group using descriptive statistics. Clinically noteworthy changes in vital signs will be listed and summarized as appropriate. A semi-automated blood pressure and pulse rate recording device with an appropriate cuff size will be utilized. Blood pressure and pulse rate will be measured after 10 minutes' rest in the semi-supine position with the subject's arm unconstrained by clothing or other material. The blood pressure should be assessed on the same arm for each subject throughout the trial. Clinical significance will be determined by investigator.

    Time frame: screening up to Day 56

  5. Number of subjects with clinically significant abnormal electrocardiograms (ECGs)

    Observed values and changes from Baseline in ECG will be summarized for each treatment group using descriptive statistics. Clinically noteworthy changes in ECG will be listed and summarized as appropriate. Clinical significance will be determined by investigator.

    Time frame: screening up to Day 28

Secondary outcomes

  1. Area under the plasma concentration-time curve from time zero to 6 hours after administration (AUC0-6)

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

  3. Time to reach maximum plasma concentration (tmax)

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

  4. Concentration observed immediately before next dosing (Cpre) (Day 28)

    Time frame: Predose (within 30 minutes prior to dosing) on Day 28

  5. Dose-normalized AUC0-6h (AUC0-6h/dose)

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

  6. Dose-normalized Cmax (Cmax/dose)

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

  7. Accumulation ratio for AUC0-6 (Racc(AUC0-6))

    Accumulation ratio for AUC will be calculated as AUC0-6, Day28 divided by AUC0-6, Day1

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

  8. Accumulation ratio for Cmax (Racc(Cmax))

    Accumulation ratio for Cmax, calculated as Cmax, Day28 divided by Cmax, Day1

    Time frame: Predose, 0.25, 0.5, 1.0, 2.0, 4.0, and 6.0 hours post-dose on Day 1 and Day 28

07

Study locations

13 sites
  • Research site
    Anniston, Alabama 36207, United States
  • Research site
    El Cajon, California 92020-4124, United States
  • Research site
    Lakewood, California 90712, United States
  • Research site
    Los Angeles, California 90048, United States
  • Research site
    Clearwater, Florida 33765, United States
  • Research site
    DeBary, Florida 32713, United States
  • Research site
    Orlando, Florida 32806, United States
  • Research site
    Grand Blanc, Michigan 48439, United States
  • Research site
    Saint Louis, Missouri 63117, United States
  • Research site
    Austin, Texas 78745, United States
  • Research site
    Sofia, 1336, Bulgaria
  • Research site
    Sofia, 1431, Bulgaria
  • Research site
    Sofia, 1612, Bulgaria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Oct 2016, 10 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 10 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2015
First posted
Sep 1, 2015
StartActual
Nov 30, 2015
Primary completionActual
Oct 4, 2016
CompletionActual
Oct 4, 2016
Last update
Oct 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02537028
Responsible party
Sponsor
First posted
Sep 1, 2015
Start date
Nov 30, 2015
Primary completion
Oct 4, 2016
Completion
Oct 4, 2016
Last update
Oct 9, 2017

Study contacts

Medical Responsible
study director · EMD Serono Research & Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion